MOESM1 of Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies
Ana Maria Giménez-Arnau, Thomas Murphy, Benjamin Trzaskoma(MDS Associates (United States)), Maria‐Magdalena Balp(Novartis (Switzerland)), Evgeniya Antonova, Donald E. Stull(IQVIA (United States)), Karin Rosén(Baylor College of Medicine), Theodore A. Omachi(University of California, San Francisco), Sheldon Spector
Cited by 0
Related Papers
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
|New England Journal of Medicine|2013|1.1k
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
|New England Journal of Medicine|2005|890
Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy
|Annals of Internal Medicine|2011|550
Optimal recall periods for patient-reported outcomes: challenges and potential solutions
|Current Medical Research and Opinion|2009|413
Early changes in organ function predict eventual survival in severe sepsis*
|Critical Care Medicine|2005|359